Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 5 of 5 entries
Sorted by: Best Match Show Resources per page
Reporting of noninferiority and equivalence randomized trials for major prostaglandins: a systematic survey of the ophthalmology literature.

Trials

Eyawo O, Lee CW, Rachlis B, Mills EJ.
PMID: 19055743
Trials. 2008 Dec 03;9:69. doi: 10.1186/1745-6215-9-69.

BACKGROUND: Standards for reporting clinical trials have improved the transparency of patient-important research. The Consolidated Standards of Reporting Trials (CONSORT) published an extension to address noninferiority and equivalence trials. We aimed to determine the reporting quality of prostaglandin noninferiority...

Cite
Eyawo O, Lee CW, Rachlis B, et al. Reporting of noninferiority and equivalence randomized trials for major prostaglandins: a systematic survey of the ophthalmology literature. Trials. 2008;9:69doi: 10.1186/1745-6215-9-69.
Eyawo, O., Lee, C. W., Rachlis, B., & Mills, E. J. (2008). Reporting of noninferiority and equivalence randomized trials for major prostaglandins: a systematic survey of the ophthalmology literature. Trials, 969. https://doi.org/10.1186/1745-6215-9-69
Eyawo, Oghenowede, et al. "Reporting of noninferiority and equivalence randomized trials for major prostaglandins: a systematic survey of the ophthalmology literature." Trials vol. 9 (2008): 69. doi: https://doi.org/10.1186/1745-6215-9-69
Eyawo O, Lee CW, Rachlis B, Mills EJ. Reporting of noninferiority and equivalence randomized trials for major prostaglandins: a systematic survey of the ophthalmology literature. Trials. 2008 Dec 03;9:69. doi: 10.1186/1745-6215-9-69. PMID: 19055743; PMCID: PMC2621118.
Copy Download .nbib Format: NLM
Specificity of prostaglandin A(1) antiserum Against prostaglandins A(1) and B(1).

FEBS letters

Raz A, Stylos WA.
PMID: 11947053
FEBS Lett. 1973 Feb 15;30(1):21-24. doi: 10.1016/0014-5793(73)80610-6.

No abstract available.

Cite
Raz A, Stylos WA. Specificity of prostaglandin A(1) antiserum Against prostaglandins A(1) and B(1). FEBS Lett. 1973;30(1):21-24doi: 10.1016/0014-5793(73)80610-6.
Raz, A., & Stylos, W. A. (1973). Specificity of prostaglandin A(1) antiserum Against prostaglandins A(1) and B(1). FEBS letters, 30(1), 21-24. https://doi.org/10.1016/0014-5793(73)80610-6
Raz, Amiram, and Stylos, William A.. "Specificity of prostaglandin A(1) antiserum Against prostaglandins A(1) and B(1)." FEBS letters vol. 30,1 (1973): 21-24. doi: https://doi.org/10.1016/0014-5793(73)80610-6
Raz A, Stylos WA. Specificity of prostaglandin A(1) antiserum Against prostaglandins A(1) and B(1). FEBS Lett. 1973 Feb 15;30(1):21-24. doi: 10.1016/0014-5793(73)80610-6. PMID: 11947053.
Copy Download .nbib Format: NLM
Shortening the induction delivery interval with prostaglandins: a randomized controlled trial of solo or in combination.

Journal of the Turkish German Gynecological Association

Mahendru R, Yadav S.
PMID: 24591967
J Turk Ger Gynecol Assoc. 2011 Jun 01;12(2):80-5. doi: 10.5152/jtgga.2011.20. eCollection 2011.

OBJECTIVE: To compare the efficacy and safety of misoprostol alone with dinoprostone followed by misoprostol, all inserted intravaginally in induction of labor at term and the obstetrical outcome.MATERIAL AND METHODS: A pilot study comprising 111 primigravidae, >37 gestational weeks...

Cite
Mahendru R, Yadav S. Shortening the induction delivery interval with prostaglandins: a randomized controlled trial of solo or in combination. J Turk Ger Gynecol Assoc. 2011;12(2):80-5doi: 10.5152/jtgga.2011.20.
Mahendru, R., & Yadav, S. (2011). Shortening the induction delivery interval with prostaglandins: a randomized controlled trial of solo or in combination. Journal of the Turkish German Gynecological Association, 12(2), 80-5. https://doi.org/10.5152/jtgga.2011.20
Mahendru, Rajiv, and Yadav, Shweta. "Shortening the induction delivery interval with prostaglandins: a randomized controlled trial of solo or in combination." Journal of the Turkish German Gynecological Association vol. 12,2 (2011): 80-5. doi: https://doi.org/10.5152/jtgga.2011.20
Mahendru R, Yadav S. Shortening the induction delivery interval with prostaglandins: a randomized controlled trial of solo or in combination. J Turk Ger Gynecol Assoc. 2011 Jun 01;12(2):80-5. doi: 10.5152/jtgga.2011.20. eCollection 2011. PMID: 24591967; PMCID: PMC3939111.
Copy Download .nbib Format: NLM
Topical Application of Hangeshashinto (TJ-14) in the Treatment of Chemotherapy-Induced Oral Mucositis.

World journal of oncology

Kono T, Satomi M, Chisato N, Ebisawa Y, Suno M, Asama T, Karasaki H, Matsubara K, Furukawa H.
PMID: 29147213
World J Oncol. 2010 Dec;1(6):232-235. doi: 10.4021/wjon263w. Epub 2011 Jan 01.

BACKGROUND: The optimal treatment of chemotherapy-induced oral mucositis is not well established. A recent study showed that hangeshashinto (TJ-14) might be useful for periodontal disease via downregulating pro-inflammatory prostaglandins in the cyclooxygenase pathway in human. Our study aimed to...

Cite
Kono T, Satomi M, Chisato N, et al. Topical Application of Hangeshashinto (TJ-14) in the Treatment of Chemotherapy-Induced Oral Mucositis. World J Oncol. 2011;1(6):232-235doi: 10.4021/wjon263w.
Kono, T., Satomi, M., Chisato, N., Ebisawa, Y., Suno, M., Asama, T., Karasaki, H., Matsubara, K., & Furukawa, H. (2010). Topical Application of Hangeshashinto (TJ-14) in the Treatment of Chemotherapy-Induced Oral Mucositis. World journal of oncology, 1(6), 232-235. https://doi.org/10.4021/wjon263w
Kono, Toru, et al. "Topical Application of Hangeshashinto (TJ-14) in the Treatment of Chemotherapy-Induced Oral Mucositis." World journal of oncology vol. 1,6 (2010): 232-235. doi: https://doi.org/10.4021/wjon263w
Kono T, Satomi M, Chisato N, Ebisawa Y, Suno M, Asama T, Karasaki H, Matsubara K, Furukawa H. Topical Application of Hangeshashinto (TJ-14) in the Treatment of Chemotherapy-Induced Oral Mucositis. World J Oncol. 2010 Dec;1(6):232-235. doi: 10.4021/wjon263w. Epub 2011 Jan 01. PMID: 29147213; PMCID: PMC5649748.
Copy Download .nbib Format: NLM
The potential of selective COX-2 inhibitors in inflammatory and other diseases.

Drugs of today (Barcelona, Spain : 1998)

Ho L, Pasinetti GM.
PMID: 12783090
Drugs Today (Barc). 2001 Mar;37(3):181-185. doi: 10.1358/dot.2001.37.3.614853.

It has been known since the 1960s that prostaglandins play a key role in inflammation, fever and pain. In 1971, Sir John Vane discovered that the efficacy of nonsteroidal antiinflammatory drugs (NSAIDs) is derived by inhibiting a key enzyme...

Cite
Ho L, Pasinetti GM. The potential of selective COX-2 inhibitors in inflammatory and other diseases. Drugs Today (Barc). 2001;37(3):181-185doi: 10.1358/dot.2001.37.3.614853.
Ho, L., & Pasinetti, G. M. (2001). The potential of selective COX-2 inhibitors in inflammatory and other diseases. Drugs of today (Barcelona, Spain : 1998), 37(3), 181-185. https://doi.org/10.1358/dot.2001.37.3.614853
Ho, Lap, and Pasinetti, Giulio Maria. "The potential of selective COX-2 inhibitors in inflammatory and other diseases." Drugs of today (Barcelona, Spain : 1998) vol. 37,3 (2001): 181-185. doi: https://doi.org/10.1358/dot.2001.37.3.614853
Ho L, Pasinetti GM. The potential of selective COX-2 inhibitors in inflammatory and other diseases. Drugs Today (Barc). 2001 Mar;37(3):181-185. doi: 10.1358/dot.2001.37.3.614853. PMID: 12783090.
Copy Download .nbib Format: NLM
Showing 1 to 5 of 5 entries